Special Issue "Anticancer Drug Discovery and Development"
Deadline for manuscript submissions: 30 September 2020.
Interests: anticancer therapy, personalized oncology, new drug development, microbiome, immunotherapy, cancer microenvironment, cancer cells culture, cancer stem cells, ILCs
Interests: molecular markers of the effectiveness of oncological treatment; epigenetic factors affecting clinical decisions
Special Issues and Collections in MDPI journals
Cancer is a serious problem that presents a huge threat to human health. Global cancer statistics have predicted that the number of cancer cases will constantly increase. During the last few years, there has been continued progress in anticancer drug development. New agents ranging from small molecules to engineered antibodies and immune modulators have been approved for cancer treatment. However, many of these drugs still cause serious adverse side effects. Targeting drugs specifically to cancer cells can minimize the toxic effects on normal, healthy cells.
This Special Issue on “Anticancer drugs discovery and development” aims to be an open forum where researchers may share their experiences and findings in this promising field. It is focused on the discovery and development of new therapeutic agents for cancer, using the newest techniques of biotechnology, pharmacology, and genetic engineering. Contributions to this issue, in the form of both original research and review articles, may cover all aspects of new anticancer approaches, including three-dimensional tumor models, nanotechnology, bio-printing, and molecular imaging.
Dr. Bartosz Tylkowski
Prof. Dr. Anna Bajek
Prof. Dr. Krzysztof Roszkowski
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Anticancer therapy
- Drug development
- Personalized cancer treatment
- 3D tumor models
- Drug resistance in cancer
- Molecular imaging